Astellas/Sutro to Codevelop Next-Gen Immunostimulatory ADCs for Cold Tumors

June 29, 2022
Astellas Pharma said on June 28 that it has inked a worldwide strategic alliance and licensing deal with San Francisco-based Sutro Biopharma to collaborate in the R&D of innovative immunostimulatory antibody-drug conjugates (iADCs). The pact brings together Sutro’s superior technology...read more